Scientific Advisors & Co-Founders
Harald Renz is Professor of Laboratory Medicine at the Philipps University of Marburg, Germany, and is specialized in clinical immunology and allergology. He is Head of the Institute of Laboratory Medicine and Pathobiochemistry - Molecular Diagnostics of the University Hospital Giessen and Marburg GmbH.
His work on disease-related animal models has let to the development of mouse models for various disease-related phenotypes (including acute and chronic airway inflammation, airway remodeling, perinatal immune-development).
He has further developed the concept of neuro-immune interaction in bronchial asthma and atopic dermatitis and is currently involved in the translation of the hygiene hypothesis from epidemiology into mechanism of action. He has published more than 200 original articles in peer-reviewed international journals. He has contributed to 87 review articles and editorials and has edited 44 book chapters.
He is an active member in several national and international scientific societies including the American Academy of Allergy, Asthma & Immunology (AAAAI), European Academy of Allergy & Clinical Immunology (EAACI), European Respiratory Society (ERS) and is currently President of the German Society of Allergology and Clinical Immunology (DGAKI).
Holger Garn is a biologist with a focus on immunobiology. Since 2003 he has been the Head of Research at the Institute of Laboratory Medicine and Pathobiochemistry - Molecular Diagnostics of the Philipps University of Marburg, where he was appointed Associate Professor in 2015.
Holger is an acknowledged expert in the field of immune mechanisms of chronic inflammatory diseases. His scientific activities involve animal and human studies in this area with specific focus on novel concepts of therapy and prevention. Professor Garn is well experienced in organizing and leading collaborative research projects with partners in academia and industry.
Scientific Advisory Boards
Secarna has established scientific advisory boards in the therapeutic areas of immuno-oncology and nephrology.
Specialists serving on our advisory boards are internationally renown experts from world-wide leading academic institutions in the U.S., UK, Canada and Germany.
They support Secarna in the endevour of discovering and developing ground-breaking, next generation, LNAplus™ based antisense oligonucleotide therapies.